Holen Sie sich die Stockscreener-App
5.05
3.44%
-0.18
Schlusskurs vom Vortag:
$5.23
Offen:
$5.13
24-Stunden-Volumen:
67,512
Relative Volume:
0.14
Marktkapitalisierung:
$8.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+9.78%
1M Leistung:
+60.32%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.73
$5.22
1-Wochen-Bereich:
$4.49
$5.49
52-Wochen-Spanne:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
61 8 8150 7400
Adresse
200 GREENHILL ROAD, EASTWOOD SA
Vergleichen Sie NEUP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
5.05 | 8.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.33 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.02 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.49 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.00 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.88 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Neuphoria Therapeutics Inc.NEUPStock Price Today - Zacks Investment Research
We're Keeping An Eye On Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Rate - Yahoo Finance
Bionomics Strategic Shift with Neuphoria Redomiciliation - Yahoo Finance
Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation - MarketWatch
Big Moves in Biotech! Neuphoria's Bold Transformation Unveiled! - Jomfruland.net
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewswire
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Results of Scheme Meeting - The Manila Times
Bionomics Limited (BNOX) Quarterly 10-Q Report - Quartz
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewswire
Bionomics CEO believes company has ‘significant, unrealized value’ - Yahoo Finance
Apeiron entities sell Bionomics shares worth $82,526 - Investing.com
Bionomics Limited announces intention to re-domicile to the United States - StockTitan
Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder - Marketscreener.com
Bionomics to Present at Biotech Showcase™ 2024 - Marketscreener.com
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms - Marketscreener.com
BNOXBionomics Limited American Depository Shares Latest Stock News & Market Updates - StockTitan
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Es liegen keine Finanzdaten für Neuphoria Therapeutics Inc (NEUP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.27%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):